Integrin-associated CD151 drives ErbB2-evoked mammary tumor onset and metastasis

Neoplasia (United States)

Volumn 14, Issue 8, 2012, Pages 678-689

  Deng, Xinyu ^a   Li, Qinglin ^b   Hoff, John ^a   Novak, Marian ^a   Yang, Helen ^c   Jin, Hongyan ^a   Erfani, Sonia F ^a   Sharma, Chandan ^b   Zhou, Pengcheng ^b   Rabinovitz, Isaac ^d   Sonnenberg, Arnoud ^e   Yi, Yajun ^f   Zhou, Peter ^a   Stipp, Christopher S ^g   Kaetzel, David M ^a   Hemler, Martin E ^b   Yang, Xiuwei H ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NETHERLANDS CANCER INSTITUTE   (Netherlands)

^f VANDERBILT UNIVERSITY   (United States)

^g UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6BETA4 INTEGRIN; CASPASE 3; CD151 ANTIGEN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOCAL ADHESION KINASE; KI 67 ANTIGEN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TETRASPANIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST METASTASIS; BREAST TUMOR; CANCER SURVIVAL; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL POLARITY; COLONY FORMATION; CONTROLLED STUDY; CYTOSKELETON; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84865216653     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12922     Document Type: Article

References (65)

1. Lohrisch C and Piccart M (2001). An overview of HER2. Semin Oncol 28, 3-11.
2. Eccles SA (2001). The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6, 393-406.
3. Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, and Ghani F (2005). Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7, R436-R443.
4. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, et al. (2002). Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20, 1800-1808.
5. Hemler ME (2001). Specific tetraspanin functions. J Cell Biol 155, 1103-1107.
6. Hemler ME (2008). Targeting of tetraspanin proteins-potential benefits and strategies. Nat Rev Drug Discov 7, 747-758.
7. Stipp CS (2010). Laminin-binding integrins and their tetraspanin partners as potential antimetastatic targets. Expert Rev Mol Med 12, e3.
8. Sadej R, Romanska H, Kavanagh D, Baldwin G, Takahashi T, Kalia N, and Berditchevski F (2010). Tetraspanin CD151 regulates transforming growth factor β signaling: implication in tumor metastasis. Cancer Res 70, 6059-6070.
9. Romanska HM and Berditchevski F (2011). Tetraspanins in human epithelial malignancies. J Pathol 223, 4-14.
10. Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR, Andzelm MM, Strominger JL, Brown M, and Hemler ME (2008). CD151 accelerates breast cancer by regulating α6 integrin function, signaling, and molecular organization. Cancer Res 68, 3204-3213.
11. Kwon MJ, Park S, Choi JY, Oh E, Kim YJ, Park YH, Cho EY, Nam SJ, Im YH, Shin YK, et al. (2012). Clinical significance of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 106, 923-930.
12. Yang XH, Flores LM, Li Q, Zhou P, Xu F, Krop IE, and Hemler ME (2010). Disruption of laminin-integrin-CD 151- focal adhesion kinase axis sensitizes breast cancer cells to ErbB2 antagonists. Cancer Res 70, 2256-2263.
13. Hemler ME (2005). Tetraspanin functions and associated microdomains. Nat Rev Mol Cell Biol 6, 801-811.
14. Sterk LM, Geuijen CA, van den Berg JG, Claessen N, Weening JJ, and Sonnenberg A (2002). Association of the tetraspanin CD151 with the laminin-bindingintegrins α3β1, α6β1, α6β4 and α7β1 in cells in culture and in vivo. J CellSci 115, 1161-1173.
15. Yang XH, Mirchev R, Deng X, Yacono P, Yang HL, Golan DE, and Hemler ME (2012). CD151 restricts α6 integrin diffusion mode. J Cell Sci 125, 1478-1487.
16. Owens DM and Watt FM (2001). Influence of β1 integrins on epidermal squamous cell carcinoma formation in a transgenic mouse model: α3β1, but not α2β1, suppresses malignant conversion. Cancer Res 61, 5248-5254.
17. Owens DM, Romero MR, Gardner C, and Watt FM (2003). Suprabasal α6β4 integrin expression in epidermis results in enhanced tumourigenesis and disruption of TGFβ signalling. J Cell Sci 116, 3783-3791.
18. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, et al. (2003). NF-kB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421, 639-643.
19. Margadant C, Raymond K, Kreft M, Sachs N, Janssen H, and Sonnenberg A (2009). Integrin α3β1 inhibits directional migration and wound re-epithelialization in the skin. J Cell Sci 122, 278-288.
20. Takeda Y, Kazarov AR, Butterfield CE, Hopkins BD, Benjamin LE, Kaipainen A, and Hemler ME (2007). Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. Blood 109, 1524-1532.
21. Ursini-Siegel J, Schade B, Cardiff RD, and Muller WJ (2007). Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7, 389-397.
22. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, and Muller WJ (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89, 10578-10582.
23. Sachs N, Kreft M, van den Bergh Weerman MA, Beynon AJ, Peters TA, Weening JJ, and Sonnenberg A (2006). Kidney failure in mice lacking the tetraspanin CD151. J Cell Biol 175, 33-39.
24. Baleato RM, Guthrie PL, Gubler MC, Ashman LK, and Roselli S (2008). Deletion of Cd151 results in a strain-dependent glomerular disease due to severe alterations of the glomerular basement membrane. Am J Pathol 173, 927-937.
25. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR, and Brown M (2004). High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 6, 263-274.
26. Debnath J and Brugge JS (2005). Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5, 675-688.
27. Frijns E, Sachs N, Kreft M, Wilhelmsen K, and Sonnenberg A (2010). EGF-induced MAPK signaling inhibits hemidesmosome formation through phosphorylation of the integrin β4. J Biol Chem 285, 37650-37662.
28. Germain EC, Santos TM, and Rabinovitz I (2009). Phosphorylation of a novel site on the β4 integrin at the trailing edge of migrating cells promotes hemidesmosome disassembly. Mol Biol Cell 20, 56-67.
29. Yang X, Kovalenko OV, Tang W, Claas C, Stipp CS, and Hemler ME (2004). Palmitoylation supports assembly and function of integrin-tetraspanin complexes. J Cell Biol 167, 1231-1240.
30. Zevian S, Winterwood NE, and Stipp CS (2010). Structure-function analysis of tetraspanin CD151 reveals distinct requirements for tumor cell behaviors mediated by α3β1 versus α6β4 integrin. J Biol Chem 286, 7496-7506.
31. Yang XW, Claas C, Kraeft SK, Chen LB, Wang ZM, Kreidberg JA, and Hemler ME (2002). Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology. Mol Biol Cell 13, 767-781.
32. Lukes L, Crawford NP, Walker R, and Hunter KW (2009). The origins of breast cancer prognostic gene expression profiles. Cancer Res 69, 310-318.
33. Rosner A, Miyoshi K, Landesman-Bollag E, Xu X, Seldin DC, Moser AR, MacLeod CL, Shyamala G, Gillgrass AE, and Cardiff RD (2002). Histological differences between ErbB/Ras and wnt pathway transgenic mammary tumors. Am J Pathol 161, 1087-1097.
34. Chatterjee G, Rosner A, Han Y, Zelazny ET, Li BL, Cardiff RD, and Perkins AS (2002). Acceleration of mouse mammary tumor virus-induced murine mammary tumorigenesis by a p53(172H) transgene-influence of FVB background identification of novel sites of on tumor latency and proviral insertion. Am J Pathol 161, 2241-2253.
35. Carriere A, Cargnello M, Julien LA, Gao H, Bonneil E, Thibault P, and Roux PP (2008). Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 18, 1269-1277.
36. Carriere A, Ray H, Blenis J, and Roux PP (2008). The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 13, 4258-4275.
37. Hynes NE and Watson CJ (2010). Mammary gland growth factors: roles in normal development and in cancer. Cold Spring Harb Perspect Biol 2, a003186.
38. Pontier SM and Muller WJ (2009). Integrins in mammary-stem-cell biology and breast-cancer progression-a role in cancer stem cells?J CellSci 122, 207-214.
39. Wiseman BS and Werb Z (2002). Stromal effects on mammary gland development and breast cancer. Science 296, 1046-1049.
40. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, and Brugge JS (2001). ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3, 785-792.
41. Brantley-Sieders DM, Zhuang G, Hicks D, Bin Fang W, Hwang Y, Cates JMM, Coffman K, Jackson D, Bruckheirner E, Muraoka-Cook RS, et al. (2008). The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest 118, 64-78.
42. 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 126, 489-502.
43. DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, and Winslow J (2011). Quantitative assays for the measurement of HER1-HER2 heterodimer-ization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res 13, R44.
44. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, Mauriac L, Katsaros D, Molina F, Theillet C, et al. (2008). A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 14, 1744-1752.
45. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al. (2002). A gene-expression signature as a predictor of survival in breast cancer. NEngl JMed 347, 1999-2009.
46. Sadej R, Romanska H, Baldwin G, Gkirtzimanaki K, Novitskaya V, Filer AD, Krcova Z, Kusinska R, Ehrmann J, Buckley CD, et al. (2009). CD151 regulates tumorigenesis by modulating the communication between tumor cells and endothelium. Mol Cancer Res 7, 787-798.
47. Novitskaya V, Romanska H, Dawoud M, Jones JL, and Berditchevski F (2010). Tetraspanin CD151 regulates growth of mammary epithelial cells in three-dimensional extracellular matrix: implication for mammary ductal carcinoma in situ. Cancer Res 70, 4698-4708.
48. Winterwood NE, Varzavand A, Meland MN, Ashman LK, and Stipp CS (2006). A critical role for tetraspanin CD151 in α3β1 and α6β4 integrin-dependent tumor cell functions on laminin-5. Mol Biol Cell 17, 2707-2721.
49. Baldwin G, Novitskaya V, Sadej R, Pochec E, Litynska A, Hartmann C, Williams J, Ashman L, Eble JA, and Berditchevski F (2008). Tetraspanin CD151 regulates glycosylation of α3β1 integrin. J Biol Chem 283, 35445-35454.
50. Jeselsohn R, Brown NE, Arendt L, Klebba I, Hu MG, Kuperwasser C, and Hinds PW (2010). Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumor-igenesis. Cancer Cell 17, 65-76.
51. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, Li HI, and Eaves CJ (2006). Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997.
52. Luo J, Yin X, Ma T, and Lu J (2010). Stem cells in normal mammary gland and breast cancer. Am J Med Sci 339, 366-370.
53. Lahlou H, Sanguin-Gendreau V, Frame MC, and Muller WJ (2012). Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo. Breast Cancer Res 14, R36.
54. Arias-Romero LE, Villamar-Cruz O, Pacheco A, Kosoff R, Huang M, Muthuswamy SK, and Chernoff J (2010). A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells. Oncogene 29, 5839-5849.
55. Haenssen KK, Caldwell SA, Shahriari KS, Jackson SR, Whelan KA, Klein-Szanto AJ, and Reginato MJ (2010). ErbB2 requires integrin α5 for anoikis resistance via Src regulation of receptor activity in human mammary epithelial cells. J Cell Sci 123, 1373-1382.
56. Hartel FV, Holl M, Arshad M, Aslam M, Gunduz D, Weyand M, Micoogullari M, Abdallah Y, Piper HM, and Noll T (2010). Transient hypoxia induces ERK-dependent anti-apoptotic cell survival in endothelial cells. Am J Physiol Cell Physiol 298, C1501-C1509.
57. Luo M and Guan JL (2010). Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis. Cancer Lett 289, 127-139.
58. Kim J, Thorne SH, Sun L, Huang B, and Mochly-Rosen D (2011). Sustained inhibition of PKCα reduces intravasation and lung seeding during mammary tumor metastasis in an in vivo mouse model. Oncogene 30, 323-333.
59. Yamada M, Sumida Y, Fujibayashi A, Fukaguchi K, Sanzen N, Nishiuchi R, and Sekiguchi K (2008). The tetraspanin CD151 regulates cell morphology and intracellular signaling on laminin-511. FEBS J 275, 3335-3351.
60. Wang H, Fu W, Im JH, Zhou Z, Santoro SA, Iyer V, DiPersio CM, Yu QC, Quaranta V, Al-Mehdi A, et al. (2004). Tumor cell α3β1 integrin and vascular laminin-5 mediate pulmonary arrest and metastasis. J Cell Biol 164, 935-941.
61. Mitchell K, Svenson KB, Longmate WM, Gkirtzimanaki K, Sadej R, Wang X, Zhao J, Eliopoulos AG, Berditchevski F, and Dipersio CM (2010). Suppression of integrin α3β1 in breast cancer cells reduces cyclooxygenase-2 gene expression and inhibits tumorigenesis, invasion, and cross-talk to endothelial cells. Cancer Res 70, 6359-6367.
62. Crew VK, Burton N, Kagan A, Green CA, Levene C, Flinter F, Brady RL, Daniels G, and Anstee DJ (2004). CD 151, the first member of the tetraspanin (TM4) superfamily detected on erythrocytes, is essential for the correct assembly of human basement membranes in kidney and skin. Blood 104, 2217-2223.
63. Sheng KC, van Spriel AB, Gartlan KH, Sofi M, Apostolopoulos V, Ashman L, and Wright MD (2009). Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur J Immunol 39, 50-55.
64. Takeda Y, Li Q, Kazarov AR, Epardaud M, Elpek K, Turley SJ, and Hemler ME (2011). Diminished metastasis in tetraspanin CD151-knockout mice. Blood 118, 464-472.
65. Wright MD, Geary SM, Fitter S, Moseley GW, Lau LM, Sheng KC, Apostolopoulos V, Stanley EG, Jackson DE, and Ashman LK (2004). Characterization of mice lacking the tetraspanin superfamily member CD151. Mol Cell Biol 24, 5978-5988.